Regencell Bioscience (NASDAQ:RGC) Stock Price Down 4.4% – Should You Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s share price was down 4.4% on Thursday . The stock traded as low as $19.75 and last traded at $19.5450. Approximately 11,985 shares changed hands during trading, a decline of 96% from the average daily volume of 282,055 shares. The stock had previously closed at $20.45.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Regencell Bioscience Stock Performance

The company’s 50 day moving average price is $27.18 and its two-hundred day moving average price is $25.61.

Regencell Bioscience (NASDAQ:RGC) last released its earnings results on Friday, May 8th. The company reported $0.00 earnings per share for the quarter.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of RGC. Seven Fleet Capital Management LP purchased a new position in shares of Regencell Bioscience during the 4th quarter valued at $92,000. Amundi purchased a new stake in shares of Regencell Bioscience during the 1st quarter worth approximately $219,000. Hudson Bay Capital Management LP bought a new stake in Regencell Bioscience in the fourth quarter worth $275,000. Bank of America Corp DE raised its stake in Regencell Bioscience by 59,113.8% during the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after purchasing an additional 17,143 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in Regencell Bioscience during the third quarter valued at $598,000. Hedge funds and other institutional investors own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.